<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04425070</url>
  </required_header>
  <id_info>
    <org_study_id>ATG-010-TN/K-001</org_study_id>
    <nct_id>NCT04425070</nct_id>
  </id_info>
  <brief_title>A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma</brief_title>
  <acronym>TOUCH</acronym>
  <official_title>A Single Arm, Open-label, and Multi-center Study to Evaluate the Safety and Primary Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Patients of Relapsed/Refractory Peripheral T- and NK/T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antengene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antengene Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is proposed with treatment of ATG-010 combined with chemotherapy regimens which&#xD;
      will be chosen by investigators (ICE [ifosfamide+carboplatin+etoposide] or GEMOX&#xD;
      [gemcitabine+oxaliplatin]), after treatments of 2 to 6 cycles transferring to ATG-010&#xD;
      monotherapy maintenance treatment, to evaluate the safety, tolerability, and primary efficacy&#xD;
      of ATG-010 in R/R PTCL and NK/T-cell lymphoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a single-arm, open-label, multi-center Phase Ib clinical study that will&#xD;
      evaluate ATG-010 combined with chemotherapy regimen selected by investigators (ICE regimen&#xD;
      ifosfamide+carboplatin+etoposide; Or GEMOX regimen: gemcitabine+oxaliplatin) sequential ATG&#xD;
      010 monotherapy maintenance, to evaluate the safety, tolerability, and primary efficacy in&#xD;
      R/R PTCL and NK/T-cell lymphoma patients. Thirty patients are planned to be enrolled (about&#xD;
      50% of patients will be enrolled in ICE and GEMOX, respectively), among which, no more than 5&#xD;
      patients will be enrolled in type of NK/T-cell lymphoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>ATG-010 + ICE ATG-010 + GEMOX</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs/SAEs</measure>
    <time_frame>18 months</time_frame>
    <description>Toxicity will be graded according to the NCI CTCAE, Version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>18 months</time_frame>
    <description>To determine the overall response rate according to Chenson 2014.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>18 months</time_frame>
    <description>Duration of time from first occurrence of CR or PR until the first date that disease progression is objectively documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>4 weeks to 18 months</time_frame>
    <description>Proportion of patients who achieve CR, PR, or SD for a minimum of 4 weeks, following the first dose of study drug (i.e., CR+PR+SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>18 months</time_frame>
    <description>Duration of time from the first dose of study drug until progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>18 months</time_frame>
    <description>Duration of time from the first dose of study drug until death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Peripheral T-cell Lymphoma</condition>
  <condition>NK/T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>ATG-010 + ICE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATG-010 60 mg/once,total twice in each cycle; on Days 4 and 11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG-010 + GEMOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATG-010 60 mg/once,total twice in each cycle; on Days 2 and 9</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>ICE [ifosfamide+carboplatin+etoposide]</intervention_name>
    <description>• Combined with ICE chemotherapy regimen:&#xD;
Ifosfamide: 5 g/m2, continuous intravenous (iv) infusion (mesna 5 g/m2 synchronously iv infusion for rescue), on Day 2;&#xD;
Carboplatin: with concentration-area under time curve (AUC)=5 (highest concentration to 800 mg), iv infusion, on Day 2;&#xD;
Etoposide l00 mg/m2, iv infusion, on Days 1-3;&#xD;
ATG-010 60 mg/once, oral, on Days 4 and 11. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW).</description>
    <arm_group_label>ATG-010 + ICE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>GEMOX [gemcitabine+oxaliplatin]</intervention_name>
    <description>• Combined with GEMOX chemotherapy regimen:&#xD;
Gemcitabine 1000 mg/m2, iv infusion, on Days 1 and 8;&#xD;
Oxaliplatin 130 mg/m2, iv infusion, on Day 1;&#xD;
ATG-010 60 mg/once, oral, on Days 2 and 9. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW).</description>
    <arm_group_label>ATG-010 + GEMOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient is willing to provide written ICF.&#xD;
&#xD;
          2. Age≥ 18 years.&#xD;
&#xD;
          3. R/R PTCL and NK/T-cell lymphoma as confirmed by histological methods according to WHO&#xD;
             classification of tumors of lymphoid tissues 2016.&#xD;
&#xD;
          4. Previously received at least one or more standard regimens including anthracycline.&#xD;
&#xD;
          5. Recurrence or the recurrence disease after the last treatment completed.&#xD;
&#xD;
          6. At least one measurable disease per modified efficacy assessment criteria (Cheson&#xD;
             2014).&#xD;
&#xD;
          7. ECOG PS 0 or 1.&#xD;
&#xD;
          8. Any toxicity caused by previously anti-tumor therapy must recovered to ≤ Grade 1&#xD;
             (NCI-CTCAE v5.0) with exception of hearing loss, alopecia, and pigmentation.&#xD;
&#xD;
          9. Expected life time longer than 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current have disease or history of central nervous system lymphoma.&#xD;
&#xD;
          2. HBV-DNA positive, or HCV-RNA positive.&#xD;
&#xD;
          3. Patients with a known history of human immunodeficiency virus (HIV) infection and/or&#xD;
             acquired immunodeficiency syndrome.&#xD;
&#xD;
          4. Received major surgery within 4 weeks of first dose of study drug&#xD;
&#xD;
          5. Known received SINE, including ATG-010.&#xD;
&#xD;
          6. Unable to swallow the tablets, suffers from malabsorption syndrome, or any other&#xD;
             gastrointestinal disease or dysfunction that may interfere with ATG-010 absorption.&#xD;
&#xD;
          7. Known allergy to ATG-010, or ICE, or GEMOX.&#xD;
&#xD;
          8. A woman who is pregnant or nursing.&#xD;
&#xD;
          9. The investigator considerations on patient's complications or other conditions may&#xD;
             affect protocol compliance or may be inappropriate for participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huiqiang Huang, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shimin Sun, M.D.</last_name>
    <phone>13701803117</phone>
    <email>jasmine.sun@antengene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junnan Li</last_name>
    <phone>18500533744</phone>
    <email>junnan.li@antengene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongmei Jing</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiqiang Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keshu Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical Universisity Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huilai Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhen Cai</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 25, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 19, 2021</last_update_submitted>
  <last_update_submitted_qc>June 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

